AcuCort applies for market approval of ISICORT® in Sweden
AcuCort AB (Spotlight Stock Market: ACUC) announces that the company has submitted a national hybrid application for approval of the company's drug candidate ISICORT® to the Swedish Medical Products Agency (MPA). A hybrid application is applicable since ISICORT® is a new dosage form and the company intends to introduce changes in its Summary of Product Characteristics (SPC) compared to the selected reference product.AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to be placed on the tongue, primarily for the treatment of severe and acute allergic reactions,